InnoProMed: The Next Akeso? Unveiling Its IVD Strategy and Proteomics-Driven Precision Medicine Platform

The biomarkers we often hear about are a broader concept, referring to any characteristic that can indicate the presence, severity, or progression of a disease in a biological process. IVD mainly detects the possibility of having the disease.Efficacy biomarkers refer to biological markers that can reflect the effects of a drug during the drug action process.They are direct or indirect indicators of biological changes produced after the interaction between drugs and organisms. The guidance for detection focuses more on screening suitable drugs for clinical use, similar to companion diagnostics.The usage volume is also considerable.This is the special role of Innovmab Therapeutics in the IVD industry, and it also represents a niche field.

At present, there is still a serious lack of precise biomarkers available for clinical use. The main reasons for the difficulty in developing effective biomarkers includeLack of pharmacodynamic-related clinical models, lack of systematic efficacy data support, and lack of standardized high-quality data leading to low result comparability, etc.The three factors of models, data, and standardization have been bottlenecks in development in the past, but since the emergence of big data and AI, these issues have seen opportunities for improvement.

Innovmab Therapeutics, as a practitioner of this trend, uses AI algorithms from the organoid multi-omics platform to establish relationships between drug efficacy and multi-omics data, screening for more precise drug efficacy biomarkers to provide important references for clinical precision medication. According to the information announcement, itsUnder ResearchLDTThe product can simultaneously detect the activity of 8 efficacy-related protein factors, providing guidance for targeted drug use based on the HER signaling pathway.Can cover a variety of indications, including breast cancer, non-small cell lung cancer, colorectal cancer, gastric cancer, pancreatic cancer, ovarian cancer, and melanoma.

We know that the recent LDT pilot in Shanghai has been implemented. In the future, the LDT-to-IVD conversion mechanism will gradually be promoted and improved. This LDT product can fully apply for transformation into an IVD kit for multi-target detection of tumor pathology slices. In addition to drug efficacy markers, Innovmab Therapeutics can also provide a series of high-value research and development enabling services, includingDiagnostic Biomarker Screening: Joint Development of Novel LDT and IVD Products, optimal indication assessment, drug repositioning, etc., fully promoting the application of proteomics technology in more fields.

Only ADCs with unique target advantages, indication space, drugability, and clinical efficacy will have significant application value and potential, and are expected to become best-in-class pipelines. This is the experiential conclusion of its investors at Akeso Biopharma. These features involve targets, clinical efficacy, and more.All require precise detection, and the only way to accomplish this prerequisite task is through accurate diagnosis.

Innovmab Therapeutics has established an organoid proteomics technology platform, characterized by targeted proteomics technology. With the integration of AI, it plays a significant role in collaborative medical testing and biopharmaceuticals, empowering scientific services, clinical testing, medication guidance, and new drug development, truly achieving a closed-loop diagnosis and treatment.Even with medication, clinical efficacy still needs to be confirmed, highlighting the indispensable role of testing.

Since genetic abnormalities and abnormal protein expression are not always consistent, and proteins are the key factors in drug action and gene function execution, the rise of proteomics, despite being recent, has a certain inevitability.It is unique content of the precision medicine era.Proteogenomics may offer a better prospect for the clinical characterization of tumors. The combination of cancer genomic atlas and clinical proteomic tumor analysis will make significant contributions to precision oncology. The full integration of proteomics into clinical trials and patient care can...Provide the right cancer treatment to patients with the correct dosage and timing.

In summary, the significance of proteomics has been well established. By employing high-throughput detection technologies and AI-driven big data analysis, personalized disease risk assessment models and health management models can be developed. These advancements make effective contributions to the prevention and treatment of chronic diseases, early warning of acute medical events, precision tumor detection, and fundamental cancer research. Moreover, from one perspective,The trend towards personalization in medicine, such as personalized medicine and precision medicine, also promotes the development of laboratory-developed tests (LDT) in clinical laboratories., which provides momentum for improvement. This is also why Innovmab Therapeutics has LDT products under development, and I believe other companies do as well.

Previously, with the popularity of next-generation sequencing, genome/transcriptome analysis has become a common task for various research teams, making it seem as if molecular diagnostics only involve DNA and RNA. However, as mentioned in the previous section, the correlation between the genome and phenotype is often not high. The process from genes to protein function involves various regulatory mechanisms and in vivo compensatory effects.The results of the genomic analysis are still in the preliminary stage.As the actual executor of life functions, proteomics has played an increasingly important role in patient stratification, drug target screening, and other aspects.

ThereforeWith proteomics detection as the core and others as auxiliary, it can improve molecular diagnostic technology, comprehensively reflect the patient's physiological status, and enhance the reliability of detection and analysis results.The successful completion of Innovmab Therapeutics' angel round and the signing of an agreement for the next round of financing indicate that the molecular diagnostics track is undergoing a qualitative change and is playing an increasingly important role among all testing tracks.

References:

1. Innovmab Therapeutics Related Information